Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNEUROPHARMACOLOGY

Dose Response to Intraventricular Glial Cell Line-Derived Neurotrophic Factor Administration in Parkinsonian Monkeys

Zhiming Zhang, Yasuyuki Miyoshi, Paul A. Lapchak, Frank Collins, Dana Hilt, Carl Lebel, Richard Kryscio and Don M. Gash
Journal of Pharmacology and Experimental Therapeutics September 1997, 282 (3) 1396-1401;
Zhiming Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuyuki Miyoshi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Lapchak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Collins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Hilt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Lebel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Kryscio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don M. Gash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A double-blinded study was conducted to evaluate the dose response of hemiparkinsonian rhesus monkeys to intracerebroventricular (ICV) injections of recombinant methionine human glial cell line-derived neurotrophic factor (GDNF). Thirty rhesus monkeys with stable hemiparkinsonian features were divided into six treatment groups (vehicle, 10, 30, 100, 300 and 1000 μg GDNF; n = 5/group). Each animal received 4 ICV administrations spaced at four week intervals. In addition, the animals were followed for 4 mo after the last injection. Standardized video taped behavioral tests were used to rate parkinsonian features using a nonhuman primate rating scale and assess side effects from treatment. Significant behavioral improvements were measured in animals receiving 100 to 1000 μg GDNF. One month after the last GDNF administration, parkinsonian features in animals receiving 100 and 1000 μg GDNF began to return to baseline levels. However, 300 μg GDNF recipients continued to display behavioral improvements. Parkinsonian features significantly improved were: bradykinesia, rigidity, posture and balance. The most common side effect was a transient weight loss after GDNF administration. Only one other side effect was observed, one animal receiving 1000 μg GDNF displayed dyskinetic movements. The results provide additional information for evaluating the possible clinical application of GDNF for treating Parkinson’s disease.

Footnotes

  • Send reprint requests to: Dr. Don Marshall Gash, Anatomy and Neurobiology, University of Kentucky Medical Center, 800 Rose Street, MN224, Lexington, KY 40536-0084.

  • ↵1 This study was supported by a contract with Amgen, Inc., Thousand Oaks, CA.

  • ↵2 Current address: Department of Anatomy and Neurobiology, University of Kentucky, College of Medicine, Lexington, KY 40536.

  • ↵3 Current address: Department of Biostatistics, University of Kentucky, Lexington, KY 40536.

  • ↵4 Current address: Department of Neuroscience, Amgen, Inc., Thousand Oaks, CA 91320.

  • ↵5 Current address: Department of Clinical Development, Amgen, Inc., Thousand Oaks, CA 91320

  • ↵6 Current address: Department of Toxicology, Amgen, Inc., Thousand Oaks, CA 91320.

  • Abbreviations:
    GDNF
    glial cell line-derived neurotrophic factor
    MPTP
    1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
    ICV
    intracerebroventricular
    • Received January 17, 1997.
    • Accepted May 2, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 3
1 Sep 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dose Response to Intraventricular Glial Cell Line-Derived Neurotrophic Factor Administration in Parkinsonian Monkeys
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNEUROPHARMACOLOGY

Dose Response to Intraventricular Glial Cell Line-Derived Neurotrophic Factor Administration in Parkinsonian Monkeys

Zhiming Zhang, Yasuyuki Miyoshi, Paul A. Lapchak, Frank Collins, Dana Hilt, Carl Lebel, Richard Kryscio and Don M. Gash
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1396-1401;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherNEUROPHARMACOLOGY

Dose Response to Intraventricular Glial Cell Line-Derived Neurotrophic Factor Administration in Parkinsonian Monkeys

Zhiming Zhang, Yasuyuki Miyoshi, Paul A. Lapchak, Frank Collins, Dana Hilt, Carl Lebel, Richard Kryscio and Don M. Gash
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1396-1401;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Novel Neuroprotectant Neurosteroids for OP Intoxication
  • Disease-Modifying Effects of Neurosteroids in Post-SE Models
  • Lacosamide and Rufinamide Against SE
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics